SeaStar Medical Holding Corporation (ICU)
NASDAQ: ICU · IEX Real-Time Price · USD
0.439
-0.034 (-7.16%)
At close: May 8, 2024, 4:00 PM
0.449
+0.010 (2.25%)
After-hours: May 8, 2024, 4:27 PM EDT

Company Description

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.

The company offers inflammatory response to fend off infections and repair damaged tissue in the body.

It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.

The company is headquartered in Denver, Colorado.

SeaStar Medical Holding Corporation
SeaStar Medical Holding logo
Country United States
Founded 2018
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Eric Schlorff

Contact Details

Address:
3513 Brighton Blvd, Suite 410
Denver, Colorado 80216
United States
Phone 844-427-8100
Website seastarmedical.com

Stock Details

Ticker Symbol ICU
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001831868
CUSIP Number 81256L104
ISIN Number US81256L1044
Employer ID 85-3681132
SIC Code 3841

Key Executives

Name Position
Eric Schlorff Chief Executive Officer, President and Executive Director
Dr. H. David Humes M.D. Co-Founder and Managing Director
Colonel Kevin Chung FACP, M.D. Chief Medical Officer
David A. Green CPA, M.B.A. Chief Financial Officer
Tom Mullen Vice President of Operations and Product Development

Latest SEC Filings

Date Type Title
May 3, 2024 DEF 14A Other definitive proxy statements
Apr 26, 2024 10-K/A [Amend] Annual report
Apr 23, 2024 PRE 14A Other preliminary proxy statements
Apr 18, 2024 8-K Current Report
Apr 17, 2024 8-K Current Report
Apr 16, 2024 10-K Annual Report
Apr 1, 2024 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 27, 2024 8-K/A [Amend] Current report
Mar 27, 2024 8-K Current Report
Mar 27, 2024 8-K Current Report